Breast Cancer study: BPET/DBT imaging vs 18F-FES
Official title FES BPET-DBT in Newly Diagnosed Breast Cancer
ClinicalTrials.gov ID: NCT05659797
What this study is testing
What is 18F-FES?
An investigational radiolabeled imaging agent being studied for breast cancer detection. is designed to bind estrogen receptors in breast tissue and emit positrons for PET imaging.
Also referred to as 18F-fluoroestradiol.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to learn how well a new imaging device that combines PET and tomosynthesis can show estrogen activity in breast cancer tumors.
- Who it's for
- Women or men 18 or older with newly diagnosed estrogen‑receptor positive breast cancer and at least one tumor 1.0 cm or larger.
- What's involved
- Participants will receive an IV injection of a radioactive estrogen tracer and then have a combined PET and tomosynthesis scan of the breast. No treatment will be changed based on the scan results.
- Time commitment
- The study lasts a few days for the imaging visit; no additional study visits are required.
- Phase 1: an early, usually small safety study
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Participants will be ≥ 18 years of age.
- Known ER positive (by immunohistochemistry) breast cancer.
- At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. mammogram, ultrasound, MRI, CT, FDG-PET/CT).
- Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this...
You likely can't join if
- Females who are pregnant or breast feeding will not be eligible for this study
- Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
- Currently taking tamoxifen or raloxifene
- Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician...
The study team makes the final eligibility decision.
Where it is enrolling
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.